RT Journal Article
T1 Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis
A1 López Sánchez, Alicia
A1 Pérez Cantero, Alba
A1 Torrado Salmerón, Carlos Félix
A1 Martín Vicente, Adela
A1 García Herrero, Víctor
A1 González Nicolás González, María Ángeles
A1 Lázaro Fernández, Alberto
A1 Tejedor Jorge, Alberto
A1 Torrado Durán, Santiago
A1 García Rodríguez, Juan José
A1 Capilla, Javier
A1 Torrado Durán, Susana
AB An experimental micellar formulation of 1:1.5 amphotericin B-sodium deoxycholate (AMB:DCH 1:1.5) was obtained and characterized to determine its aggregation state and particle size. The biodistribution, nephrotoxicity, and efficacy against pulmonary aspergillosis in a murine model were studied and compared to the liposomal commercial formulation of amphotericin B after intravenous administration. The administration of 5 mg/kg AMB:DCH 1:1.5 presented 2.8-fold-higher lung concentrations (18.125 ± 3.985 μg/g after 6 daily doses) and lower kidney exposure (0.391 ± 0.167 μg/g) than liposomal commercial amphotericin B (6.567 ± 1.536 and 5.374 ± 1.157 μg/g in lungs and kidneys, respectively). The different biodistribution of AMB:DCH micelle systems compared to liposomal commercial amphotericin B was attributed to their different morphologies and particle sizes. The efficacy study has shown that both drugs administered at 5 mg/kg produced similar survival percentages and reductions of fungal burden. A slightly lower nephrotoxicity, associated with amphotericin B, was observed with AMB:DCH 1:1.5 than the one induced by the liposomal commercial formulation. However, AMB:DCH 1:1.5 reached higher AMB concentrations in lungs, which could represent a therapeutic advantage over liposomal commercial amphotericin B-based treatment of pulmonary aspergillosis. These results are encouraging to explore the usefulness of AMB:DCH 1:1.5 against this disease.</jats:p>
PB ASM Journals
SN 0066-4804
YR 2018
FD 2018-06-26
LK https://hdl.handle.net/20.500.14352/98759
UL https://hdl.handle.net/20.500.14352/98759
LA eng
NO López Sánchez, A., Pérez Cantero, A., Torrado Salmerón, C. F. et al. «Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis». Antimicrobial Agents and Chemotherapy, vol. 62, n.o 7, julio de 2018, pp. e00489-18. DOI.org (Crossref), https://doi.org/10.1128/AAC.00489-18.
NO Universidad Complutense de Madrid
NO Ministerio de Economía, Comercio y Empresa (España)
NO Fondo Europeo de Desarrollo Regional
NO Comunidad de Madrid
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 8 abr 2025